+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida



Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida



Chest 122(4): 1292-1298



Objectives: To determine the completion rate and tolerability of short-course rifamycin and pyrazinamide treatment of latent tuberculosis infection (LTBI) in HIV-infected patients through a comprehensive community-based program. Design: Prospective cohort, with comparison to a historical control group. Patients: Of 3,118 patients with HIV infection screened for LTBI between February 1999 and March 2001, 135 patients were placed on rifamycin/pyrazinamide for 2 months under directly observed therapy and were compared to a historical group comprised of 93 HIV-infected patients who were placed on self-administered treatment of isoniazid for 12 months between 1996 and 1998. Results: Of 135 patients receiving rifamycin/pyrazinamide, 124 patients (92%) completed treatment; 5 patients had to discontinue treatment due to side effects (allergic skin reactions (n=4), hepatitis (n=1)). The completion rate of the historical group who received isoniazid therapy was 61% (57 of 93 patients; p<0.001); none of those who received isoniazid experienced significant side effects. Conclusion: In our experience, a comprehensive, community-based program of rifamycin/pyrazinamide for LTBI achieved significantly higher adherence than that of traditional isoniazid therapy, and thus may provide improved tuberculosis prevention in a community with high prevalence of HIV-infected patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011355506

Download citation: RISBibTeXText

PMID: 12377855


Related references

Short-Course Rifamycin and Pyrazinamide Treatment for Latent Tuberculosis Infection in Patients with HIV Infection. Chest Journal 122(4): 1292-1298, 2002

Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. Chest 124(6): 2112-2118, 2003

Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest 119(3): 833-837, 2001

Tolerability and utility of two-month short-course rifampin/pyrazinamide treatment of latent tuberculosis infection. Journal of Investigative Medicine 48(1): 170A, January, 2000

Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. International Journal of Tuberculosis and Lung Disease 6(11): 995-1000, 2002

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. Clinical Infectious Diseases 39(2): 289-289, 2004

Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection. Clinical Infectious Diseases 44(3): 464-5; Author Reply 465, 2007

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Annals of Internal Medicine 137(8): 640-647, 2002

Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clinical Infectious Diseases 39(12): 1764-1771, 2004

Rifampin and pyrazinamide for treatment of latent tuberculosis infection. Clinical Infectious Diseases 42(6): 892; Author Reply 892-3, 2006

Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection. Expert Opinion on Drug Safety 3(3): 187-198, 2004

Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?. American Journal of Respiratory and Critical Care Medicine 167(6): 809-810, 2003

Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection. Chest 123(3): 967-967, 2003

Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. JAMA 288(2): 165-166, 2002

Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. Mmwr. Morbidity and Mortality Weekly Report 51(44): 998-999, 2002